7L7U image
Entry Detail
PDB ID:
7L7U
EMDB ID:
Keywords:
Title:
BG505 SOSIP reconstructed from a designed nanoparticle, BG505 SOSIP-T33-31 (Component B)
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2020-12-30
Release Date:
2021-08-04
Method Details:
Experimental Method:
Resolution:
3.80 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:BG505 SOSIP.v5.2(7S) - gp120
Chain IDs:A, C, E
Chain Length:505
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Description:BG505 SOSIP.v5.2(7S) - gp41
Chain IDs:B, D, F
Chain Length:145
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Ligand Molecules
Primary Citation

Abstact

Engineered ectodomain trimer immunogens based on BG505 envelope glycoprotein are widely utilized as components of HIV vaccine development platforms. In this study, we used rhesus macaques to evaluate the immunogenicity of several stabilized BG505 SOSIP constructs both as free trimers and presented on a nanoparticle. We applied a cryoEM-based method for high-resolution mapping of polyclonal antibody responses elicited in immunized animals (cryoEMPEM). Mutational analysis coupled with neutralization assays were used to probe the neutralization potential at each epitope. We demonstrate that cryoEMPEM data can be used for rapid, high-resolution analysis of polyclonal antibody responses without the need for monoclonal antibody isolation. This approach allowed to resolve structurally distinct classes of antibodies that bind overlapping sites. In addition to comprehensive mapping of commonly targeted neutralizing and non-neutralizing epitopes in BG505 SOSIP immunogens, our analysis revealed that epitopes comprising engineered stabilizing mutations and of partially occupied glycosylation sites can be immunogenic.

Legend

Protein

Chemical

Disease

Primary Citation of related structures